The Antibody-Drug Conjugate (ADC) Market Is Promising


New Delhi, July 15, 2022 (GLOBE NEWSWIRE) — The global ADC market is growing at an impressive CAGR. Growing advancements in bonding technologies coupled with extensive research and development in the medical field are driving the growth of the global ADC market…

A recent study by the strategic consulting and market research firm BlueWeave Consulting revealed that the Global ADC Market was worth USD 4,053.7 million in 2021. The market is further expected to reach USD 14,484.2 million by 2027 with a significant CAGR of 25.2% during the forecast period, i.e., 2022- 2027. Rising incidence of cancer cases across the globe is propelling the growth of the global ADC (Antibody-Drug Conjugate) market. For example, according to the American Cancer Society, the estimated number of new cancer cases and deaths recorded for 2021 were around 1.9 million and 608,570, respectively, in the United States. In the coming years, the development of ADC drugs will be facilitated by the increasing number of government health care programs and grants awarded to certain research organizations. These factors, coupled with an increasing number of FDA approvals, are positively impacting the growth of the global ADC market.

Growing number of ADC drug trials create lucrative opportunities for market growth

The American Cancer Society estimates that there are 36 ongoing trials with more than 20 ADCs combined with immuno-oncology (IO) therapies. With over 100 estimated clinical trials underway worldwide in 2019, there has been a growing trend of ADCs being produced in the market. Moreover, with the increasing number of Food & Drug Administration (FDA) approvals, the ADC class of drugs has started to become an emerging drug in the market. However, some strict regulations have rendered more than 20% of ADC trials null and void. The FDA found that more than 12 of the ADC drugs are in Phase II or Phase III (final stage) clinical trials, suggesting a growing number of approvals the FDA could issue in the coming years, providing more opportunities for growth in the market, as these drugs may begin to be accessible to low- and middle-income countries that have long been locked out of ADC drugs due to skyrocketing prices.

Request sample report @ https://www.blueweaveconsulting.com/report/antibody-drug-conjugates-adc-market/report-sample

Downstream processing and technological issues with ADC are expected to hamper market growth

The companies of antibody-drug conjugates market report that the downstream treatment process is a significant challenge that hinders their growth. Capabilities to produce suitable chemical linkers to connect monoclonal antibodies and cytotoxic drugs is the biggest downstream process challenge for cost-effective ADC manufacturing and development and is expected to hamper the market growth.

Impact of COVID-19 on the global ADC market

The COVID-19 pandemic has had a mixed impact on the global ADC market. ADC has been shown to be beneficial in the treatment of cancer. According to the American Cancer Society, approximately 1.8 million new cancer cases and nearly 606,500 cancer deaths were recorded in 2020. The number of cases recorded in 2020 was higher than the number of cases in 2019, which was 1.7 million. Thus, the increasing incidence of cancer has led to an increasing demand for ADCs during the pandemic. However, due to the lockdown and supply chain disruptions, factory operations have been curtailed, resulting in reduced clinical studies and the unavailability of important raw materials, monoclonal antibodies (mAb ), linkers and technologies involved in the production of ADCs. All these factors have had a negative impact on the growth of the global Antibody-Drug Conjugates market.

The cleavable type segment accounted for the highest market share in the growth of the global ADC market

On the basis of type, the global ADC market is segmented into cleavable linkers and non-cleavable linkers. The cleavable linker segment accounted for the largest market share in 2021. Increasing approval rate and pipeline molecules, coupled with the ongoing trial of cleavable linker are the major growth drivers for the segment. For example, in September 2021, the Japanese Ministry of Health, Labor and Welfare (MHLW) announced that it was issuing a license for PADCEV (enfortumab vedotin), as it has been shown to be profoundly effective in combating unresectable urothelial carcinoma, which has increased anti-cancer chemotherapy capabilities, according to research conducted by Seagen Inc. and Astellas Pharma Inc. The ministry-approved ADC happens to be a cleavable linker ADC used to treat the urothelial cancer.

Please see the press release from Global ADC Market: https://www.blueweaveconsulting.com/press-release/adc-market-set-for-promising-growth-forecast-to-reach-usd-14-4-billion-by-2027

North America dominates the global ADC market

Based on region, the global ADC market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America region held the largest market share in 2021. On the other hand, Asia-Pacific region is expected to hold the largest CAGR during the forecast period. The increase in cancer cases in Asia-Pacific can be attributed to various causes, including unhealthy lifestyles influenced by Western culture, increased consumption of alcohol and tobacco, and increased pollution in South and Southeast Asia. Another factor contributing to the growth in cancer rates includes the growing geriatric population.

Global ADC MarketCompetitive landscape

Major companies in the global ADC market are F. Hoffmann-La Roche AG, Seagen, Inc. (Seattle Genetics Inc.), Daiichi Sankyo Company Ltd., AstraZeneca plc, Pfizer Inc., GlaxoSmithKline plc, Gilead Sciences, Inc., Takeda Pharmaceutical Company Limited, Genentech Inc., Astellas Pharma Inc. and other leading players. The growing number of clinical trials for ADC products, including Trastuzumab Deruxtecan (DS-8201a), Sacituzumab govitecan, Mirvetuximab Soravtansine (IMGN853), Enfortumab Vedotin, Trastuzumab Duocarmazine (SYD985), and others, have demonstrated the increasing competition in the breast market as well as ovarian cancer, which is expected to increase competition in the market.

Don’t miss the global ADC market trading opportunity. Consult our analysts to gain crucial insights and facilitate the growth of your business.

The report’s in-depth analysis provides insights into the Global ADC Market’s growth potential, upcoming trends, and statistics. It also highlights the factors driving the forecast of the total market size. The report promises to provide recent technology trends in the global ADC market along with industry insights to help decision makers take sound strategic decisions. In addition, the report also analyzes market growth drivers, challenges, and competitive dynamics.

RECENT DEVELOPMENTS:

  • August 2021: Roche announced that the pivotal phase III POLARIX trial evaluating Polivy (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) versus MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), met the primary endpoint by demonstrating a significantly improved progression-free survival rate for patients diagnosed with untreated diffuse large B-cell lymphoma (DLBCL). Safety results in this trial were similar to previous ones.

Report Scope:

Attribute Details
Years considered Historical data – 2018-2021
Base year – 2021
Forecast – 2022 – 2027
Facts Covered Revenue in millions of dollars
Market coverage United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, Saudi Arabia, United Arab Emirates, South Africa
Product/service segmentation By type, by application, by end user, by region
Key players The major players in the global ADC market are F. Hoffmann-La Roche AG, Seagen, Inc. (Seattle Genetics Inc.), Daiichi Sankyo Company Ltd., AstraZeneca plc, Pfizer Inc., GlaxoSmithKline plc, Gilead Sciences, Inc., Takeda Pharmaceutical Company Limited, Genentech Inc., Astellas Pharma Inc. and other leading players.

By type

  • Cleavable linker
  • Non-cleavable linker

By app

  • Leukemia
  • Multiple myeloma
  • Lymphoma
  • Breast cancer
  • Urothelial cancer and bladder cancer
  • Others

By end users

  • Research institutes
  • Biotechnology companies
  • Hospitals
  • Clinics

By region

  • North America
  • Europe
  • Asia-Pacific (APAC)
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Please find a related report below:

About Us

BlueWeave Consulting (BWC) provides comprehensive market intelligence (MI) solutions to businesses regarding various online and offline products and services. We offer comprehensive market research reports by analyzing qualitative and quantitative data to improve the performance of your business solution. BWC has built its reputation from scratch by providing quality inputs and building lasting relationships with its customers. We are an up-and-coming MI digital solutions company providing agile support to make your business efforts a success.

Contact us:

BlueWeave Consulting & Research Pvt. ltd

+1 866 658 6826 | +1 425 320 4776 | +44 1865 60 0662

[email protected]
https://www.blueweaveconsulting.com/

https://www.linkedin.com/company/blueweaveconsulting/

Previous We need an affordable insurance plan to maintain internet and phone connectivity
Next Abortion haters decide to block online ads for reproductive services